His research in the 1970s had focused
on tumor viruses because they were thought to alter human genes, thereby causing cancer.
Around 1984, when a student of his pointed out that Duesberg had not attended a West Coast meeting of scientists working
on tumor viruses, he suddenly realized that he was no longer being invited to the informal meetings.
Not exact matches
A new generation of oncolytic
viruses are entering late - stage clinical trials, repurposing smallpox and herpesvirus to take
on tough
tumors
The issue now is not whether
viruses cause human
tumors (as perhaps they may,
on occasion) but rather how much can be learned from
tumor virology about the mechanisms by which human
tumors arise.
The immune system depends
on molecules called T cell receptors
on the surface of T cells to recognize and respond to foreign antigens from
virus - infected cells,
tumors and other threats.
For some cancer patients,
viruses engineered to zero in
on tumor cells work like a wonder drug.
To bring the wrath of the immune system down
on tumors, researchers have tried shooting them up with a variety of molecules and
viruses.
Don Diamond, a virologist at the City of Hope Cancer Center near Los Angeles, agrees: his extensive research
on CMV and cancer has convinced him the
virus does not cause
tumors.
For the CRISPR trial, a UPenn - led team wants to remove T cells from patients and use a harmless
virus to give the cells a receptor for NY - ESO - 1, a protein that is often present
on certain
tumors but not
on most healthy cells.
These cells are
on high alert for pathogens such as
viruses, bacteria and even
tumor cells, signaling the body's T - cell immune fighters into action when sensing harmful invaders.
The result — still a preliminary finding — illustrates the potential for improved cancer treatment through saddling a cancer - killing
virus on the back of a
tumor - targeting immune cell.
With respect to biological applications, the group is focusing
on how cellular heterogeneity and cell - to - cell communication drive ensemble - level decision - making in the immune system, with an emphasis
on «two - body» interaction (e.g., host cell -
virus interactions, innate immune control of adaptive immunity,
tumor infiltration by immune cells).
After two years of post-graduate studies at the Max Planck Institute for Biochemistry in Munich, Dr. Jaenisch set his sights
on a postdoctoral position in the United States, and joined Arnold Levine at Princeton University to work with
tumor viruses in mammalian systems.
If the
virus is igniting a fire within the
tumor, we want to see if we can use these immune modulators to pour gas
on the flames.»
From there they showed that cancer cells had lost structural polarity, resulting in random distribution of CAR receptors
on their surface, thereby allowing the
virus to attach to and infect the
tumor cells.
Other scalable systems include cell lines based
on the Henrietta Lacks
tumor (HeLa) and baby hamster kidney (BHK - 21) cells for adenovirus serotype 5 (Ad5) and herpes simplex
virus 1 (HSV - 1) production (4, 40, 41).
Hunter's breakthrough, which set the story in motion, was a product of basic research
on a chicken RNA
tumor virus: the 1979 discovery of the first tyrosine kinase paved the way for our understanding of how cells perceive their environment and respond appropriately to growth signals.
«It will critically inform the medical community
on whether this combination approach, using an oncolytic
virus followed by a checkpoint inhibitor, will be the next step in the successful treatment of brain
tumors in both people and pets.»